Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.56 |
| ▸ | PARP1 | P09874 | 1/20 | 0.56 |
| ▸ | PARP11 | Q9NR21 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | HTR5A | P47898 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30564582 | 1.00 | PARP10 (0.56) | PARP10PARP1PARP11ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL549603 | 0.98 | PARP10 (0.55) | PARP10PARP1PARP11ALDH1A1MAPT | |
| SCHEMBL3111834 | 0.88 | MAPT (0.50) | PARP10PARP1PARP11ALDH1A1MAPT | |
| SCHEMBL30634161 | 0.88 | MAPT (0.50) | PARP10PARP1PARP11ALDH1A1MAPT | |
| SCHEMBL5467021 | 0.86 | MAPT (0.49) | PARP10PARP1PARP11ALDH1A1MAPT | |
| SCHEMBL12461 | 0.83 | DRD2 (0.59) | PARP10PARP1PARP11ALDH1A1MAPT | |
| SCHEMBL15601745 | 0.81 | PARP10 (0.56) | PARP10PARP1PARP11ALDH1A1MAPT | |
| SCHEMBL9055504 | 0.78 | ALDH1A1 (0.44) | PARP10PARP1PARP11ALDH1A1MAPT | |
| SCHEMBL16602943 | 0.77 | — | — | |
| SCHEMBL6966954 | 0.77 | HTR5A (0.53) | PARP10PARP1PARP11ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 418 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | BASF SE (DE) | 2019-03-05 | — | — | US | claimed |
| CN-116145156-B | Indoline compound preparation method based on organic electronic synthesis | 六盘水师范学院 | 2026-05-15 | — | — | CN | disclosed |
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | REMEDY PLAN, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260092051-A1 | PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME | HANMI PHARMACEUTICAL CO LTD (KR) | 2026-04-02 | — | — | US | disclosed |
| US-12522587-B2 | Cancer treatments targeting cancer stem cells | REMEDY PLAN, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4605089-A1 | COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K | Mekanistic Therapeutics LLC (US) | 2025-08-27 | — | — | EP | disclosed |
| US-12325698-B2 | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | HANMI PHARM. CO., LTD. (KR) | 2025-06-10 | — | — | US | disclosed |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-05-29 | — | — | US | disclosed |
| EP-4540240-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | Monte Rosa Therapeutics AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| CN-119822910-A | Method for catalyzing heterogeneous reduction of nitrogen-containing heterocyclic compound by using magnesium metal | 延安大学 | 2025-04-15 | — | — | CN | disclosed |
| EP-0888349-A1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | Novartis AG (CH) | 1999-01-07 | — | — | EP | disclosed |
| US-5773618-A | PYRROLOQUINOLINONE DERIVATIVES | SANKYO COMPANY, LIMITED (JP) | 1998-06-30 | — | — | US | disclosed |
| US-5736534-A | HYPERPROLIFERATIVE DISEASES; INHIBITORS OF PROTEIN-TYROSINE KINASES SUCH AS EPIDERMAL GROWTH FACTOR RECEPTOR; BRAIN, LUNG, BREAST CANCER; PSORIASIS AND BENIGN PROSTATE HYPERPLASIA | PFIZER INC. (US) | 1998-04-07 | — | — | US | disclosed |
| CN-1172809-A | Tricyclic compounds having fungicidal activity, their preparation and their use | SANKYO CO (JP) | 1998-02-11 | — | — | CN | disclosed |
| EP-0807631-A1 | Tricyclic compounds having fungicidal activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1997-11-19 | — | — | EP | disclosed |
| WO-1997027199-A1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1997-07-31 | — | — | WO | disclosed |
| CN-1141633-A | 4-heterocyclic substituted quinazoline derivatives, process for their preparation and their use as anticancer agents | PFIZER (US) | 1997-01-29 | — | — | CN | disclosed |
| EP-0746554-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| WO-1995023141-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1995-08-31 | — | — | WO | disclosed |
| US-4186199-A | Indolo-,1,2-dihydroindolo-, and 1,2,6,7-tetrahydroindolo [1,7-ab][1,5] benzodiazepines | AMERICAN HOECHST CORPORATION (US) | 1980-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12325698-B2 | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | DPYD, TYMS, TYMP | PARP10 901/4885PARP1 122/4885PARP11 400/4885 |
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | MCL1, MALT1, BCL6 | PARP10 3986/4885PARP1 474/4885PARP11 842/4885 |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | PARP10 705/4885PARP1 307/4885PARP11 319/4885 |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | STOM, SPOP, TTR | PARP10 4841/4885PARP1 4793/4885PARP11 4883/4885 |
| US-20260092051-A1 | PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME | FLT3, FLT1, ADK | PARP10 1055/4885PARP1 638/4885PARP11 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.